Latest & greatest articles for verapamil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on verapamil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on verapamil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for verapamil

1. [A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia]. (Abstract)

[A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia]. To compare the safety and efficacy of intravenous adenosine with verapamil in terminating acute episodes of paroxysmal supraventricular tachycardia.A randomized, multicenter trial to evaluate dose response in patients receiving adenosine and to compare the effects of adenosine with those of verapamil. A total of 122 patients (...) with a tachycardia electrocardiographically consistent with paroxysmal supraventricular tachycardia were entered into the protocol. The adenosine group (n = 60) received sequential intravenous bolus doses of 3, 6, and 12 mg of adenosine to terminate PSVT and verapamil group (n = 62) were administrated 5mg or additional 5mg intravenously. Clinical variables and the time interval from the initiation of treatment to the termination of the supraventricular tachycardia, as well as the time from the initial effective

2003 Zhonghua nei ke za zhi [Chinese journal of internal medicine] Controlled trial quality: uncertain

2. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis

The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

3. Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. (Abstract)

Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. The safety and efficacy of verapamil and adenosine in the acute termination of supraventricular tachycardia were compared in a randomized double-crossover trial. Of 32 eligible patients with either spontaneous or induced narrow complex tachycardia, seven (22%) patients experienced conversion to sinus rhythm with carotid sinus massage. The other 25 patients were randomly assigned (...) to receive either adenosine (n = 14) or verapamil (n = 11). Relative drug efficacies were 100% for adenosine versus 73% for verapamil, p = NS. Adenosine given at less than or equal to 120 micrograms/kg caused conversion in 12 (86%) of 14 patients. The other two patients required 20 mg adenosine for conversion. After conversion the systolic blood pressure increased significantly in the adenosine group but not in the verapamil group. Reinitiation of tachycardia occurred in two (14%) of 14 patients

1992 American heart journal Controlled trial quality: uncertain

4. Comparative study of electrocardiographic changes in patients of acute mania receiving verapamil or lithium carbonate. Full Text available with Trip Pro

Comparative study of electrocardiographic changes in patients of acute mania receiving verapamil or lithium carbonate. TO compare the ECG changes in patients of acute mania receiving verapamil and lithium carbonate.Verapamil used in resistant manic patients not responding to any drug therapy, should be considered for its side effects on cardiovascular system. It causes bradycardia and myocardial infarction in risk patients. So it is important to take clinical and other relevant history and do (...) ECG before the patient to put on verapamil drug therapy.Patients with acute mania were randomized to receive lithium (n =25) or verapamil (n=25) in a 4-wk double-blind comparative study. Both groups were homogeneous with regard to demographic and disease variables. After giving first dose of verapamil, patients were observed for any cardiovascular side effects and ECG changes during the study. The study parameters were recorded at the baseline, after 7 d and 28 d of trial medication.The Unpaired t

2015 Journal of clinical and diagnostic research : JCDR Controlled trial quality: uncertain

5. Comparative study of intralesional verapamil with intralesional Triamcinolone Acetonide in treatment of keloids and hypertrophic scars: a systematic review and meta-analysis

Comparative study of intralesional verapamil with intralesional Triamcinolone Acetonide in treatment of keloids and hypertrophic scars: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

6. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. (Abstract)

Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. To investigate the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide on post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass.In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five (...) treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks and pasireotide 300 μg as a single dose. Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM).Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean ± SEM 3.9 ± 0.2

2019 obesity & metabolism Controlled trial quality: uncertain

7. Verapamil targets membrane energetics in <i>Mycobacterium tuberculosis</i>. Full Text available with Trip Pro

Verapamil targets membrane energetics in Mycobacterium tuberculosis. Mycobacterium tuberculosis kills more people than any other bacterial pathogen and is becoming increasingly untreatable due to the emergence of resistance. Verapamil, an FDA-approved calcium channel blocker, potentiates the effect of several antituberculosis (anti-TB) drugs in vitro and in vivo This potentiation is widely attributed to inhibition of the efflux pumps of M. tuberculosis, resulting in intrabacterial drug (...) accumulation. Here, we confirmed and quantified verapamil's synergy with several anti-TB drugs, including bedaquiline (BDQ) and clofazimine (CFZ), but found that the effect is not due to increased intrabacterial drug accumulation. We show that, consistent with its in vitro potentiating effects on anti-TB drugs that target or require oxidative phosphorylation, the cationic amphiphile verapamil disrupts membrane function and induces a membrane stress response similar to those seen with other membrane-active

2018 Antimicrobial Agents and Chemotherapy

8. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials

Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

9. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. (Abstract)

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies.After T, 2 mg, in open conditions for 1 month, 69 patients were randomly assigned to be administered T, 2 mg, combined with V, 180 mg, plus a placebo or T, 2 mg, plus A, 5 mg, once a day in a double-blind fashion

2003 American journal of kidney diseases : the official journal of the National Kidney Foundation Controlled trial quality: uncertain

10. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. (Abstract)

Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. To assess the safety and efficacy of intravenous adenosine in terminating acute episodes of paroxysmal supraventricular tachycardia.Two prospective, double-blind, randomized, placebo-controlled trials to evaluate dose response in patients receiving adenosine and to compare the effects of adenosine with those (...) trial, cumulative response rates after 6 mg followed, if necessary, by 12 mg of adenosine were 57.4% and 93.4%, and after 5 mg followed, if necessary, by 7.5 mg of verapamil were 81.3% and 91.4%. The average time after injection to termination of tachycardia by adenosine was 30 seconds. Adenosine caused adverse effects in 36% of patients, but they lasted less than 1 minute and were usually mild.Adenosine in graded doses up to 12 mg rapidly and effectively terminates acute episodes of paroxysmal

1990 Annals of internal medicine Controlled trial quality: predicted high

11. Effects of subcutaneous verapamil on the duration of local anesthetic blockade. (Abstract)

Effects of subcutaneous verapamil on the duration of local anesthetic blockade. To determine whether a subcutaneous injection of verapamil will provide local anesthesia and whether a mixture of lidocaine and verapamil will prolong the anesthetic effect of lidocaine alone.Randomized, double-blind, placebo-controlled study.Preanesthetic area of a large metropolitan teaching hospital.20 volunteers.All volunteers received 4 injections of normal saline, verapamil, lidocaine, and lidocaine-verapamil (...) injection. The time elapsed until the person was again able to perceive sharp from a 26-gauge needle prick was measured at all 4 sites. When compared with the effects of normal saline, subcutaneous verapamil provided local anesthesia to pinprick. The mixture of verapamil and lidocaine also provided anesthesia to pinprick, but the duration of effect was less than that provided by lidocaine alone. The use of verapamil alone and in combination with lidocaine was associated with a marked degree of erythema

1995 Journal of clinical anesthesia Controlled trial quality: uncertain

12. Verapamil therapy for Prinzmetal's variant angina: comparison with placebo and nifedipine. (Abstract)

Verapamil therapy for Prinzmetal's variant angina: comparison with placebo and nifedipine. This study was performed (1) to assess the efficacy and safety of verapamil in patients with variant angina, and (2) to compare verapamil and nifedipine in patients with this clinical syndrome. In 27 patients, placebo and verapamil were administered in a long-term randomized, and double-blind study of 9 months' duration. In comparison to placebo, verapamil reduced the frequency of angina, nitroglycerin (...) usage, transient episodes of electrocardiographic S-T segment deviation (as assessed by 2-channel Holter monitoring), and hospitalizations required for clinical instability. Subsequently, 23 patients were treated with nifedipine in a nonblind fashion for 2 months, and this agent exerted a beneficial effect similar to that of verapamil. Finally, gated equilibrium blood pool scintigraphy, performed in 10 patients at rest and during exercise during treatment with placebo, verapamil, and nifedipine

1982 The American journal of cardiology Controlled trial quality: uncertain

13. Individualizing treatment with verapamil for cluster headache patients. (Abstract)

Individualizing treatment with verapamil for cluster headache patients. Verapamil is currently the best available prophylactic drug for patients experiencing cluster headaches (CHs). Published papers usually state 240 to 480 mg taken in three divided doses give good results, ranging from 50% to 80%; others mention higher doses--720, even 1200 mg per day. In clinical practice we found we needed to adapt dosage to individual's time of attacks, in particular giving higher doses before going to bed (...) to suppress severe nocturnal episodes. A few only required 120 mg daily. We therefore evolved a scheme for steady and progressive drug increase until satisfactory control had been achieved.To find the minimum dose of verapamil required to prevent episodic and chronic cluster headaches by supervising each individual and adjusting the dosage accordingly.Consecutive patients with episodic or chronic CH (satisfying International Headache Society (IHS) criteria) were started on verapamil 40 mg in the morning

2004 Headache

14. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). (Abstract)

A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). The International Verapamil/Trandolapril Study (INVEST) demonstrated comparable efficacy between verapamil SR and atenolol antihypertensive treatment strategies for clinical outcomes and blood pressure (BP) control in hypertensive patients with coronary artery disease (N (...) of treatment.Patients were assigned to either a verapamil SR or atenolol strategy to achieve Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure BP goals. Trandolapril and/or hydrochlorothiazide were recommended as add-on agents.Depressive symptoms were measured by the Center for Epidemiologic Studies-Depression (CES-D) scale.CES-D scores improved 1.45 points (p < .001) after 1 year in patients assigned to the verapamil SR strategy, whereas a nonsignificant

2005 Psychosomatic Medicine

15. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. (Abstract)

Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has been

2000 Cochrane

16. Verapamil

Verapamil Verapamil Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Verapamil Verapamil Aka: Verapamil , Calan , Phenylalkamine From (...) of severe May progress into Verapamil ineffective against Sinus Node or AV Node dysfunction without Severe Concurrent Intravenous use V. Indications (90% effective) Terminates sustained reentry within AV Node Terminates AV Node limb of reentrant circuit Terminates AV Node reentry s Slows ventricular response to Verapamil is highly effective Used for acute treatment and prevention VI. Drug Interaction Increases ( ) level (see contraindications above) VII. Pharmacokinetics Peak effect seen within 3-5

2018 FP Notebook

17. Verapamil

Verapamil Top results for verapamil - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for verapamil The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

18. Intravenous diltiazem hydrochloride rather than verapamil for resistant paroxysmal supraventricular tachycardia. Full Text available with Trip Pro

Intravenous diltiazem hydrochloride rather than verapamil for resistant paroxysmal supraventricular tachycardia. 8279162 1994 02 10 2018 11 13 0093-0415 159 5 1993 Nov The Western journal of medicine West. J. Med. Intravenous diltiazem hydrochloride rather than verapamil for resistant paroxysmal supraventricular tachycardia. 598-9 Peitz T J TJ eng Journal Article United States West J Med 0410504 0093-0415 CJ0O37KU29 Verapamil EE92BBP03H Diltiazem AIM IM Diltiazem administration & dosage (...) therapeutic use Drug Tolerance Humans Hypotension chemically induced Injections, Intravenous Tachycardia, Paroxysmal drug therapy Tachycardia, Supraventricular drug therapy Verapamil adverse effects therapeutic use 1993 11 1 1993 11 1 0 1 1993 11 1 0 0 ppublish 8279162 PMC1022357 Am J Cardiol. 1992 Sep 1;70(6):587-92 1510006 Am Heart J. 1992 Jun;123(6):1543-9 1595533

1993 Western Journal of Medicine

19. Comparison of the effects of antiarrhythmic drugs flecainide and verapamil on fKv1.4ΔN channel currents in Xenopus oocytes Full Text available with Trip Pro

Comparison of the effects of antiarrhythmic drugs flecainide and verapamil on fKv1.4ΔN channel currents in Xenopus oocytes To study the effects of Na(+) channel blocker flecainide and L-type Ca(2+) channel antagonist verapamil on the voltage-gated fKv1.4ΔN channel, an N-terminal-deleted mutant of the ferret Kv1.4 K(+) channel.fKv1.4ΔN channels were stably expressed in Xenopus oocytes. The K(+) currents were recorded using a two-electrode voltage-clamp technique. The drugs were administered (...) through superfusion.fKv1.4ΔN currents displayed slow inactivation, with a half-inactivation potential of -41.74 mV and a slow recovery from inactivation (τ=1.90 s at -90 mV). Flecainide and verapamil blocked the currents with IC(50) values of 512.29 ± 56.92 and 260.71 ± 18.50 μmol/L, respectively. The blocking action of the drugs showed opposite voltage-dependence: it was enhanced with depolarization for flecainide, and was attenuated with depolarization for verapamil. Both the drugs exerted state

2012 Acta pharmacologica Sinica

20. Verapamil

Verapamil Verapamil Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Verapamil Verapamil Aka: Verapamil , Calan , Phenylalkamine From (...) of severe May progress into Verapamil ineffective against Sinus Node or AV Node dysfunction without Severe Concurrent Intravenous use V. Indications (90% effective) Terminates sustained reentry within AV Node Terminates AV Node limb of reentrant circuit Terminates AV Node reentry s Slows ventricular response to Verapamil is highly effective Used for acute treatment and prevention VI. Drug Interaction Increases ( ) level (see contraindications above) VII. Pharmacokinetics Peak effect seen within 3-5

2015 FP Notebook